Enochian Biosciences (OTCMKTS:ENOB) Stock Price Up 10.9%

Shares of Enochian Biosciences Inc (OTCMKTS:ENOB) rose 10.9% during mid-day trading on Wednesday . The stock traded as high as $6.20 and last traded at $5.28, approximately 117,524 shares were traded during trading. An increase of 138% from the average daily volume of 49,381 shares. The stock had previously closed at $4.76.

The firm has a 50-day moving average price of $4.65 and a 200-day moving average price of $5.73.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENOB. Northern Trust Corp acquired a new stake in shares of Enochian Biosciences in the second quarter worth $49,000. Marshall Wace LLP acquired a new stake in shares of Enochian Biosciences in the first quarter worth $60,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Enochian Biosciences in the second quarter worth $69,000. Wells Fargo & Company MN acquired a new stake in shares of Enochian Biosciences in the second quarter worth $72,000. Finally, United Capital Financial Advisers LLC acquired a new stake in shares of Enochian Biosciences in the second quarter worth $105,000.

Enochian Biosciences Company Profile (OTCMKTS:ENOB)

Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.

Featured Article: Preferred Stock

Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.